Amgen’s Phase 2 data for their obesity drug, MariTide, showed promising results with participants on average losing 20% of their weight after one year of treatment. This puts MariTide in competition with other blockbuster drugs like Zepbound and Wegovy. The drug offers convenient less frequent dosing options for consumers and has shown no plateau in weight loss potential. Amgen is planning to move forward with Phase 3 testing based on the positive preliminary data. While some analysts believe MariTide falls short of market expectations, others see potential in its differentiated profile. Overall, the drug shows promise as a competitive weight loss option in the market.
Source link
Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator
